Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:28:15.186Z.
Calculation as of: 2026-10-06T16:28:15.186Z.
Quote observation: 2026-10-06T16:25:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dd4f1084baaf1fdd631c8004248db7003b46672aad8e0139030c30c223f55df
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$16.76M
EV/EBIT Ratio
N/A
TTM Avg
197.54x
3Y Avg
1437.98x
5Y Avg
1437.98x
Market Cap
$16.48M
EV/EBIT Ratio
N/A
TTM Avg
188.96x
3Y Avg
135.60x
5Y Avg
135.60x
Market Cap
$17.81M
EV/EBIT Ratio
N/A
TTM Avg
64.12x
3Y Avg
126.81x
5Y Avg
126.81x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $16.98M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.19M | N/A | 19.21x | 19.21x | 19.21x |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | N/A | 197.54x | 1437.98x | 1437.98x |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.48M | N/A | 188.96x | 135.60x | 135.60x |
| Cosmos Health Inc. (COSM)vs › | $17.81M | N/A | 64.12x | 126.81x | 126.81x |
| BioCardia, Inc. (BCDA)vs › | $16.00M | N/A | 33.55x | 33.49x | 33.49x |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.60M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
